Allovir Inc reports results for the quarter ended in June - Earnings Summary

Kalaris Therapeutics

06/08/2021 19:33

* Allovir Inc  ALVR.OQ  reported a quarterly adjusted loss of 60
cents​​ per share for the quarter ended in June. The mean
expectation of four analysts for the quarter was for a loss
of 49 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Allovir Inc's reported EPS for the quarter was a loss of 60
cents​.
* The mean earnings estimate of analysts had fallen by about 14%
in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Allovir Inc shares had risen by 2.3% this quarter and
lost 47.5% so far this year.
* The company reported a quarterly loss of $37.59 million.
* Wall Street's median 12-month price target for Allovir Inc is
$50.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated August 6 at 06:33 p.m.  ​All
figures in US dollars unless otherwise stated